MedTrace Logo

Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer

NCT02271581 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2020-11-04

No results posted yet for this study

Summary

There is a growing body of evidence that implicates inflammation as a mechanism of disease progression and reduced survival in patients with advanced cancer. Elevated c-reactive protein levels have been shown to be associated with reduced performance status, specific cancer related symptoms and reduced overall survival. C-reactive protein levels are a surrogate for IL-6 expression. IL-6 is part of an inflammatory signature predicting cancer recurrence. VeriStrat® is a multivariate test which measures protein expression related to a host/tumor interaction mediated by inflammation. The investigators hope to examine the relationship between quality of life outcomes per FACT-L survey and correlate them with changes in c-reactive protein levels and the VeriStrat® status. The hypothesis of this study is that the remarkable survival benefit in the Temel study is mediated by reduced inflammation with improvement of symptom control.

Conditions

  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung

Sponsors & Collaborators

  • Leo W. Jenkins Cancer Center

    lead OTHER

Principal Investigators

  • Geoffrey Stroud, PharmD, BCOP, CPP · Brody School of Medicine at ECU

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2019-04-19
Completion
2019-04-19

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02271581 on ClinicalTrials.gov